

1 **Functional alteration of innate T cells in critically ill Covid-19 patients**

2
3 Youenn Jouan^{1,2,3,4,9}, Antoine Guillon^{1,2,3,8}, Loïc Gonzalez^{1,2,8}, Yonatan Perez^{1,2,3}, Stephan
4 Ehrmann^{1,2,3}, Marion Ferreira^{2,5}, Thomas Daix⁵, Robin Jeannet⁵, Bruno François⁵, Pierre-
5 François Dequin^{1,2,3}, Mustapha Si-Tahar^{1,2}, Thomas Baranek^{1,2,7} and Christophe Paget^{1,2,7,9}

6
7 ¹INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.

8 ²Université de Tours, Faculté de Médecine de Tours, France. ³Service de Médecine Intensive
9 et Réanimation, Centre Hospitalier Régional Universitaire, Tours, France. ⁴Service de chirurgie
10 cardiaque et de réanimation chirurgicale cardio-vasculaire, Centre Hospitalier Régional
11 Universitaire, Tours, France. ⁵Intensive Care Unit, Dupuytren Teaching Hospital, Limoges,
12 France; Inserm CIC1435, Dupuytren Teaching Hospital, Limoges, France; Inserm UMR 1092,
13 University of Limoges, Limoges, France. ⁵Service de pneumologie, Centre Hospitalier
14 Régional Universitaire, Tours, France.

15 ^{7,8}Contributed equally

16 ⁹Correspondance should be address to: youenn.jouan@chu-tours.fr or
17 christophe.paget@inserm.fr

18
19 **Short title:** Innate T cells in Covid-19

20
21 **Keywords:** innate T cells, inflammation, viral infection, Covid-19.

22
23 **Number of words:** 3,812

24
25 **Abbreviations:** Covid-19, Coronavirus disease 19; ICU, intensive care unit; IFN, interferon;
26 IL, interleukin; MAIT, Mucosal associated invariant T; iNKT, invariant Natural Killer T.

27
28
29
30
31
32
33
34 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 **Abstract**

36 Covid-19 can induce lung infection ranging from mild pneumonia to life-threatening acute
37 respiratory distress syndrome (ARDS). Dysregulated host immune response in the lung is a key
38 feature in ARDS pathophysiology. However, cellular actors in Covid-19-driven ARDS are
39 poorly understood. Here, we dynamically analyzed the biology of innate T cells, a
40 heterogeneous class (MAIT, $\gamma\delta$ T and iNKT cells) of T lymphocytes, presenting potent anti-
41 infective and regulatory functions. Patients presented a compartmentalized lung inflammation
42 paralleled with a limited systemic inflammation. Circulating innate T cells of critically ill
43 Covid-19 patients presented a profound and persistent phenotypic and functional alteration.
44 Highly activated innate T cells were detected in airways of patients suggesting a recruitment to
45 the inflamed site and a potential contribution in the regulation of the local inflammation.
46 Finally, the expression of the CD69 activation marker on blood iNKT and MAIT cells at
47 inclusion was predictive of disease severity. Thus, patients present an altered innate T cell
48 biology that may account for the dysregulated immune response observed in Covid-19-related
49 acute respiratory distress syndrome.

50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

69 **Introduction**

70 In December 2019 were first reported in Wuhan, China, pneumonia cases due to a coronavirus,
71 the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), a novel strain related
72 to SARS-CoV and MERS-CoV, responsible for recent outbreaks. Disease presentation related
73 with SARS-CoV-2 (Coronavirus disease, Covid-19), can vary from mild disease to life-
74 threatening acute respiratory distress syndrome (ARDS). ARDS is caused by a sustained and
75 dysregulated immune response triggered in the lung after initial insult, resulting in alteration of
76 alveolar-capillary membrane permeability and perturbed tissue repair¹. This pathological
77 process leads to interstitial and alveolar oedema that profoundly impairs gas exchange.
78 However, the cellular and molecular factors that are responsible for this aberrant and persistent
79 inflammatory response are poorly understood². In SARS-CoV infection, delayed type I IFN
80 response together with high viral loads were associated with defective adaptive response and
81 exaggerated tissue damage³. During severe SARS-CoV-2 infection, elevated pro-inflammatory
82 cytokines levels (*e.g.* IL-6 and TNF- α) were associated with more severe cases, supporting an
83 inflammatory hypothesis⁴⁻⁶. In addition, T cell lymphopenia has been correlated with disease
84 severity suggesting a role for these cells in the pathophysiology of severe Covid-19^{5,6}. Besides
85 classical adaptative CD4⁺ and CD8⁺ T cells, the T cell compartment comprises several lineages
86 of cells endowed with both innate and adaptive properties that are referred to as unconventional
87 or innate T cells (iT cells)⁷. This heterogeneous class of T cells comprises three main lineages
88 including Mucosal-Associated Invariant T (MAIT), $\gamma\delta$ T and invariant Natural Killer T (iNKT)
89 cells. They are restricted to quasi-monomorphic non-classical major histocompatibility
90 complex and have emerged as key players in mucosal immunity and inflammatory response⁸⁻
91 ¹¹. Given their versatile functions, iT cells emerge as interesting targets in the context of Covid-
92 19-driven ARDS. First, iT cells mainly populate mucosal tissues including the lung and have
93 the ability to promptly produce substantial amounts of inflammatory cytokines such as IFN- γ
94 and IL-17A, two key cytokines in anti-infective response at barrier sites. Moreover, iT cells can
95 fine-tune the intensity and flavour of the host immune response shaping the magnitude of the
96 adaptive response. They can also participate in the process of the resolution of inflammation
97 including tissue repair and regeneration¹²⁻¹⁴, a critical step that is highly altered during ARDS.
98 Despite these pivotal functions, the putative contribution of iT cells in the pathophysiological
99 process of ARDS has never been explored.

100 Here, we dynamically assessed the relative frequencies and functions of iT cells in biological
101 fluids of thirty patients with severe Covid-19 admitted to intensive care unit (ICU). Our analysis
102 indicated that iT cells from critically ill Covid-19 patients displayed a phenotype of activated

103 cells associated with changes in their cytokine profile. Importantly, activated iT cells populated
104 the airways of patients presenting a strong local inflammation. In addition, the activation status
105 of blood iT cells on admission was predictive of the level of hypoxia during the course of
106 infection. Thus, our study indicates that an alteration in iT cell biology may account for the
107 sustained host immune response dysregulation observed in Covid-19-driven ARDS.

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137 **Results and Discussion**

138

139 *Lymphopenia and compartmentalized lung inflammation characterized critically ill Covid-* 140 *19 patients*

141 Thirty patients admitted in ICU for severe Covid-19 were included. Baseline characteristics of
142 the patients are presented in **Table 1**. Median duration of symptoms before admission in ICU
143 was 10 days (8; 14), and ultimately, 24 patients (80 %) required invasive mechanical ventilation
144 (20 at admission). Among these mechanically ventilated patients, all presented an ARDS, 21
145 (70 %) received neuromuscular blockade, 18 (60 %) were placed on prone position and one
146 patient required extra-corporeal membrane oxygenation. On CT scan, we observed typical
147 bilateral diffuse ground-glass lesions in severe Covid-19 patients (**Supplementary Figure 1A**).
148 Upon enrolment, most of Covid-19 patients (22/30) presented mild to severe lymphopenia (0.75
149 $\times 10^9/L \pm 0.06$) (**Figure 1A**) accompanied by a higher neutrophil-to-lymphocyte ratio as
150 compared to age- and sex-matched controls (**Figure 1B**). As reported¹⁵, we observed a positive
151 correlation between the degree of lymphopenia and the Sequential Organ Failure Assessment
152 (SOFA) score (**Figure 1C**). Similarly, the lymphopenia was more pronounced in patients under
153 invasive mechanical ventilation as compared to patients who did not require invasive
154 mechanical ventilation (**Figure 1D**). Among the 30 critically ill Covid-19 patients, one died at
155 day 2 after inclusion and 14 (46.7%) were still in ICU at day 15, including 9 still under invasive
156 mechanical ventilation. The remaining 15 patients improved and were discharged from ICU to
157 other wards.

158 Although the circulating levels of the inflammatory mediators IL-1 β and IL-6 were significantly
159 higher in Covid-19 patients as compared to age- and sex-matched controls (**Figure 1E**), the
160 detected amounts were relatively low, as previously reported⁶. Of note, the levels of plasma IL-
161 1RA were high suggesting an active anti-inflammatory process (**Supplementary Figure 1B**).
162 As judged by IFN- α 2 levels, the type I IFN response, a critical component of the anti-viral
163 response¹⁶ was also low in the blood compartment of patients as compared to controls (**Figure**
164 **1E**). To monitor the local inflammation, we analyzed the same mediators in the supernatants of
165 endotracheal aspirates (ETA) of matched Covid-19 patients (**Figure 1E**). Strikingly, the
166 amounts of IL-6, IL-1 β and to a lesser extent IFN- α 2 were sky high in the airways suggesting
167 an intense local inflammation upon ICU admission (**Figure 1F**). Collectively, our data indicate
168 a compartmentalized inflammation in patients with severe Covid-19.

169

170 ***Blood innate T cell decrease in Covid-19 patients is paralleled with their presence in the***
171 ***airways***

172 While a T cell lymphopenia has been described in severe Covid-19 patients⁶, the innate T cell
173 compartment has not been investigated yet. Detailed analysis of circulating iT cells within total
174 T lymphocytes indicated a profound decrease in MAIT (~ 6-fold) and iNKT (~ 7-fold) relative
175 proportions in critically ill Covid-19 patients (**Figure 2A**) despite some comorbidities such as
176 obesity and/or diabetes can also partly contribute to this observation^{17,18}. In the meantime, the
177 relative proportion of $\gamma\delta$ T cells remained unchanged (**Figure 2A**). However, by focusing on
178 subsets based on TCR repertoire, we observed that the frequency of $V\delta 2^+$ was slightly decreased
179 while the $V\delta 1\delta 2^-$ cells were increased (**Figure 2A**). Of note, no significant differences could be
180 observed for the $V\delta 1^+$ subset (**Figure 2A**). This may indicate a particular contribution of this
181 $\gamma\delta$ T subset - likely $V\delta 3^+$ - during Covid-19 as suggested in other viral infections¹⁸.

182 The decrease in circulating MAIT and iNKT cells may have multiple causes. First, we
183 interrogated whether this could be a consequence of activation-induced TCR internalization.
184 However, mean fluorescence intensity for TCR expression indicated no modulation for the
185 iNKT TCR between patients and controls (**Supplemental Figure 2A**) while an increase
186 intensity was observed for the MAIT TCR of patients. In addition, the levels of intracellular
187 TCR $V\alpha 7.2$ expression in T cells of patients did not indicate any signs of MAIT TCR
188 internalization (**Supplemental Figure 2B**).

189 Another explanation could be their migration into the airways of patients. Thus, we monitored
190 the putative presence of iT cells in ETA of Covid-19 patients under mechanical ventilation
191 (**Table 1**). We were able to recover cells - containing more than 1% of lymphocytes - in 12
192 ETA samples out of 21, enabling a further analysis of iT cells. MAIT and $\gamma\delta$ T cells were
193 detected in airways of all patients with an analysable lymphocyte compartment (**Figure 2B**).
194 Of note, airway iNKT cells were virtually undetectable in all samples. Interestingly, the
195 frequency of MAIT cells but not of $\gamma\delta$ T cells was higher in the airways as compared to blood
196 of matched-patients (**Figure 2B**) suggesting that the presence of MAIT cells in the airways
197 might be dependent on an active recruitment mechanism rather than blood vessel leakage due
198 to the alveolar-capillary barrier disruption. Furthermore, the presence of iT cells in ETA was
199 associated with a higher level of the chemoattractants for T cells CXCL10 and CXCL12¹⁹
200 (**Figure 2C**). Of note, one could argue that other causes such as increased cell death might
201 account in this phenomenon²⁰. Altogether, these data indicate a decrease in circulating MAIT
202 and iNKT cells that may be a consequence of their recruitment into the airways.

203

204 *Innate T cells displayed an altered functional profile in Covid-19 patients*

205 Phenotypic analysis of iT cell in blood of Covid-19 patients showed an increased expression of
206 the activation marker CD69 in all subsets (**Figure 3A**). This phenotype was associated with a
207 higher level of IL-18 in the plasma of patients (**Supplemental Figure 3**), a cytokine associated
208 to iT cell activation during viral infections²¹⁻²³. In parallel, we observed an increased level of
209 blood PD-1-expressing iT cells in patients suggesting a certain level of exhaustion (**Figure 3A**).
210 Of importance, the levels of CD69 and PD-1-expressing MAIT and $\gamma\delta$ T cells were significantly
211 higher in ETA compared to blood in matched patients (**Figure 3B**), which further support the
212 possible migration of activated blood iT cells into the lungs.

213 In addition, cytokine production by fresh blood iT cells was analyzed after short-term
214 PMA/ionomycin stimulation. Circulating MAIT and iNKT, and to a lesser extent $\gamma\delta$ T cells from
215 Covid-19 patients produced less IFN- γ as compared to cells from healthy donors (**Figure 3C**).
216 In the meantime, this was paralleled with an increased ability of iT cells from patients to
217 produce IL-17A (**Figure 3C**) although the levels detected were relatively low. This could be
218 partially explained by the migration of IFN- γ -producing iT cells to the lung tissue. In line with
219 the acute inflammation in the lung of Covid-19 patients²⁴, the levels of IFN- γ and IL-17A were
220 more elevated in the supernatants of ETA compared to plasma of matched patients (**Figure 3D**).
221 Interestingly, they were present at higher concentration in iT cell-containing ETA samples
222 (**Figure 3E**) suggesting that iT cells may contribute to the production of IFN- γ and IL-17A in
223 airways of critically ill Covid-19 patients. Collectively, our data indicate a functional alteration
224 of iT cells in Covid-19 patients.

225

226 *Alteration in innate T cell biology is persistent and correlates with disease severity*

227 To gain insight into their temporal changes during Covid-19, the frequency and phenotype of
228 blood iT cells was monitored in patients during their stay in the ICU. We observed a decrease
229 in the frequency of MAIT cells at day 7 and then it was maintained to day 14 (**Figure 4A**). The
230 proportion of CD69- and PD-1-expressing MAIT cells followed a similar trend (**Figure 4A**).
231 The relative proportion of circulating iNKT cells was stable in critically ill Covid-19 patients
232 during their stay in ICU regardless of their clinical course (**Figure 4B**). The level of CD69-
233 expressing iNKT cells was reduced at day 7 and 14 while no significant changes could be
234 observed for PD-1 expression on iNKT cells while (**Figure 4B**). Similar to MAIT cells, the
235 relative proportion of $\gamma\delta$ T cells in was reduced at day 7 and a further decrease was noticed at
236 day 14 (**Figure 4C**). Regarding their phenotype, the levels of circulating PD-1-expressing $\gamma\delta$ T

237 cells was stable in patients while the relative proportion of their CD69-expressing counterparts
238 was decreased at day 7 and 14 (**Figure 4C**).

239 Finally, we interrogated whether alterations in iT cell biology could be predictive of the clinical
240 course of critically ill Covid-19 patients especially regarding the level of hypoxia, measured by
241 the PaO₂/FiO₂ ratio, a routine clinical variable for ARDS management¹. Thus, we compared
242 multiple iT cell parameters on admission to the level of hypoxia at day 7. Although no
243 correlation could be observed for $\gamma\delta$ T cells, we observed that CD69 expression on MAIT and
244 iNKT cells was positively correlated to the PaO₂/FiO₂ ratio indicating a reduced level of
245 hypoxia (**Figure 4D**). Notably, no additional correlation could be observed for MAIT and iNKT
246 cells based on the other iT cell-related parameters including PD-1 expression and cytokine
247 production.

248 Altogether, these data indicate a persistent alteration in iT cell activation in Covid-19 patients
249 and the levels of activation on MAIT and iNKT cells upon admission can be predictive of
250 disease severity.

251

252 **Methods**

253

254 **Clinical study design, patient population and approval**

255 Patients (>18 years old) admitted in ICU with positive SARS-CoV-2 RT-PCR testing were
256 prospectively included in this study, from March 18th 2020 to April 17th 2020. The study was
257 conducted in one ICU from an academic hospital (Tours, France). All patients or their next of
258 kin gave consent for participation in the study. This work was part of an ongoing study
259 exploring immune response during community-acquired pneumonia (ClinicalTrials.gov
260 identifier: NCT03379207). The study was approved by the ethic committee “Comité de
261 Protection de Personnes Ile-de-France 8” under the agreement number 2017-A01841-52, in
262 accordance with the national laws. Blood samples from healthy volunteers (age- and sex-
263 matched) were obtained from the “Etablissement Français du Sang”.

264

265 **Reagents and antibodies**

266 Staining was performed using antibodies (**Table S1**) from Biolegend (San Diego, CA, USA)
267 and Miltenyi Biotec (Bergish Gladbach, Germany). PBS-57 glycolipid-loaded and control
268 CD1d tetramers (BV421-conjugated) as well as 5-OP-RU-loaded and control MR1 tetramers
269 (BV421-conjugated) were obtained from the National Institute of Allergy and Infectious
270 Diseases Tetramer Facility (Emory University, Atlanta, GA). Dead cells were stained with
271 LIVE/DEAD® Fixable Aqua Dead Cell Stain kit (ThermoFisher Scientific, Illkirch, France).

272

273 **Human cell isolation**

274 *PBMC*

275 Peripheral Blood Mononuclear Cells (PBMC) were enriched by density gradient
276 centrifugations using Histopaque-1077 solution (Sigma-Aldrich) according to the
277 manufacturer’s instructions. Red blood cells were removed using a red blood cell lysis buffer
278 (Sigma-Aldrich).

279

280 *Endotracheal aspirates (ETA)*

281 ETAs were collected from Covid-19 patients who were under invasive mechanical ventilation.
282 Then, ETAs were weighted and incubated in PBS (5 ml/g) with 1 mM Dithiothreitol for 30 min
283 at 4°C under gentle agitation. After centrifugation, supernatants were collected and cell pellets
284 were filtered through a 100 µm cell strainer. Red blood cells were removed using a red blood

285 cell lysis buffer and then cells from ETA were passed through a 40 µm cell strainer prior
286 staining for flow cytometry.

287

288 **Cytokine measurement**

289 Cytokines were measured in sera and supernatants of ETA using the Bio-Plex Pro Human
290 cytokines screening panel (Bio-Rad, Marnes-la-Coquette, France) in a multiplex fluorescent
291 bead assay (Luminex), according to the manufacturer's instructions.

292

293 **Flow cytometry**

294 Cells were stained with antibodies to surface epitopes and viability dye (LIVE/DEAD Fixable
295 Aqua Dead Cell Stain). For cytokine profile analysis, cells were stimulated for 4 h in RPMI1640
296 complete medium containing PMA (100 ng/ml) and ionomycin (1 µg/ml) in presence of protein
297 transport inhibitor cocktail (eBioscience) added 1 hour after stimulation. For intracellular
298 staining, cells were fixed and permeabilized using the Fixation/Permeabilization Solution Kit
299 (BD Biosciences). Cells were stained with APC-conjugated mAb against IL-17A and PE-
300 conjugated mAb against IFN-γ. Events were acquired on a MACS Quant (Miltenyi Biotec)
301 cytometer. Analyses were performed by using the VenturiOne software (Applied Cytometry;
302 Sheffield, UK).

303

304 **Statistical analysis**

305 All statistical analysis was performed by using GraphPad Prism software. The statistical
306 significance was evaluated by using non-parametric unpaired Mann-Whitney *U* tests in order
307 to compare the means of biological replicates in each experimental group. In some cases, the
308 non-parametric Wilcoxon matched-pairs signed rank test was used. Results with a P value of
309 <0.05 were considered significant. ns: not significant; **p* < 0.05; ***p* < 0.01; ****p* < 0.001.).
310 Correlation calculation between two parameters has been performed using the Spearman's rho
311 test.

312

313

314

315

316

317

318

319 **Author contributions**

320 Y.J., A.G., S.E., P-F.D., M.S., T.B. and C.P. designed the research; L.G., Y.P., M.F., T.D., R.J.,
321 T.B. and C.P collected the data; Y.J., L.G., T.B. and C.P. analysed the data; Y.J. and C.P. wrote
322 the manuscript with the input of all authors.

323

324 **Acknowledgments**

325 This work was supported by the Agence Nationale de la Recherche “JCJC program” (ANR-19-
326 CE15-0032-01) and by the Fondation du Souffle, with the “Fond de recherche en Santé
327 Respiratoire”. M.S. and C.P. are supported by Inserm. Y.J., A.G., Y.P., S.E. and P-F.D. were
328 supported by the CHU of Tours. M.F., T.B. and L.G. are supported by the University of Tours.
329 We thank the NIH tetramer core facility (Emory University) for providing CD1d tetramers. We
330 acknowledge all healthcare co-workers involved in the ICU department at the Bretonneau
331 Hospital, especially Aurélie Aubrey, Delphine Chartier, Véronique Siméon and Julien
332 Bontemps for their excellent management of patient samples and clinical data. Annick Legras,
333 Denis Garot, Emmanuelle Mercier, Charlotte Salmon-Gandonnière, Laetitia Bodet-Contentin,
334 Marlène Morisseau, Stephan Mankikian and Walid Darwiche are acknowledged for patient
335 inclusions. We thank all the patients and their families for their trust and confidence in our
336 work.


337

338 **References**

- 339 1. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. *N Engl*
340 *J Med.* 2017;377(6):562-572. doi:10.1056/NEJMra1608077
- 341 2. Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome.
342 *Nat Rev Dis Primers.* 2019;5(1):18. doi:10.1038/s41572-019-0069-0
- 343 3. Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated Type I Interferon and
344 Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-
345 Infected Mice. *Cell Host Microbe.* 2016;19(2):181-193. doi:10.1016/j.chom.2016.01.007
- 346 4. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes
347 and immunosuppression. *Lancet.* 2020;395(10229):1033-1034. doi:10.1016/S0140-
348 6736(20)30628-0
- 349 5. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-
350 19 in Wuhan, China. *Clin Infect Dis.* March 2020. doi:10.1093/cid/ciaa248
- 351 6. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and
352 moderate coronavirus disease 2019. *J Clin Invest.* April 2020. doi:10.1172/JCI137244
- 353 7. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family
354 of unconventional T cells. *Nat Immunol.* 2015;16(11):1114-1123. doi:10.1038/ni.3298
- 355 8. Crosby CM, Kronenberg M. Tissue-specific functions of invariant natural killer T cells.
356 *Nat Rev Immunol.* 2018;18(9):559-574. doi:10.1038/s41577-018-0034-2
- 357 9. Toubal A, Nel I, Lotersztajn S, Lehuen A. Mucosal-associated invariant T cells and
358 disease. *Nat Rev Immunol.* 2019;19(10):643-657. doi:10.1038/s41577-019-0191-y
- 359 10. McCarthy NE, Eberl M. Human $\gamma\delta$ T-Cell Control of Mucosal Immunity and
360 Inflammation. *Front Immunol.* 2018;9:985. doi:10.3389/fimmu.2018.00985
- 361 11. Trottein F, Paget C. Natural Killer T Cells and Mucosal-Associated Invariant T Cells in
362 Lung Infections. *Front Immunol.* 2018;9:1750. doi:10.3389/fimmu.2018.01750
- 363 12. Nielsen MM, Witherden DA, Havran WL. $\gamma\delta$ T cells in homeostasis and host defence
364 of epithelial barrier tissues. *Nat Rev Immunol.* 2017;17(12):733-745. doi:10.1038/nri.2017.101
- 365 13. Hinks TSC, Marchi E, Jabeen M, et al. Activation and In Vivo Evolution of the MAIT
366 Cell Transcriptome in Mice and Humans Reveals Tissue Repair Functionality. *Cell Rep.*
367 2019;28(12):3249-3262.e5. doi:10.1016/j.celrep.2019.07.039
- 368 14. Paget C, Trottein F. Mechanisms of Bacterial Superinfection Post-influenza: A Role for
369 Unconventional T Cells. *Front Immunol.* 2019;10:336. doi:10.3389/fimmu.2019.00336
- 370 15. Katze MG, He Y, Gale M. Viruses and interferon: a fight for supremacy. *Nat Rev*
371 *Immunol.* 2002;2(9):675-687. doi:10.1038/nri888

- 372 16. Magalhaes I, Pingris K, Poitou C, et al. Mucosal-associated invariant T cell alterations
373 in obese and type 2 diabetic patients. *J Clin Invest.* 2015;125(4):1752-1762.
374 doi:10.1172/JCI78941
- 375 17. Lynch L, O'Shea D, Winter DC, Geoghegan J, Doherty DG, O'Farrelly C. Invariant
376 NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer
377 and obesity. *Eur J Immunol.* 2009;39(7):1893-1901. doi:10.1002/eji.200939349
- 378 18. Mackay CR. Chemokine receptors and T cell chemotaxis. *J Exp Med.* 1996;184(3):799-
379 802. doi:10.1084/jem.184.3.799
- 380 19. Tyznik AJ, Verma S, Wang Q, Kronenberg M, Benedict CA. Distinct requirements for
381 activation of NKT and NK cells during viral infection. *J Immunol.* 2014;192(8):3676-3685.
382 doi:10.4049/jimmunol.1300837
- 383 20. Loh L, Wang Z, Sant S, et al. Human mucosal-associated invariant T cells contribute to
384 antiviral influenza immunity via IL-18-dependent activation. *Proc Natl Acad Sci USA.*
385 2016;113(36):10133-10138. doi:10.1073/pnas.1610750113
- 386 21. Tsai C-Y, Liong KH, Gunalan MG, et al. Type I IFNs and IL-18 regulate the antiviral
387 response of primary human $\gamma\delta$ T cells against dendritic cells infected with Dengue virus. *J*
388 *Immunol.* 2015;194(8):3890-3900. doi:10.4049/jimmunol.1303343
- 389 22. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses.
390 The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and
391 naming it SARS-CoV-2. *Nat Microbiol.* 2020;5(4):536-544. doi:10.1038/s41564-020-0695-z
392

393 **Figures:**



394

395 **Figure 1: Inflammatory status of critically ill patients with Covid-19.** **A**, Lymphocyte count
 396 in whole blood from critically ill Covid-19 patients (n = 30) was analyzed at day 1 post
 397 admission. Individuals and means ± SEM are depicted. **B**, Neutrophil-to-lymphocyte ratio in
 398 the whole blood of healthy donors (n = 20) and patients (n = 30) was determined by flow
 399 cytometry. Individuals and means ± SEM are shown. **C**, Spearman's rank correlation of SOFA
 400 and lymphocyte counts in Covid-19 patients. **D**, Lymphocyte counts at day 1 in patients with (n
 401 = 21) or without (n = 9) mechanical ventilation. Individuals and means ± SEM are depicted. **E**,
 402 Levels of IL-1β, IL-6, IL-1RA and IFN-α2 in the plasma of healthy donors (n = 10) and severe
 403 Covid-19 patients (n = 30). Individuals and means ± SEM are shown. **F**, Levels of IL-1β, IL-6,
 404 IL-1RA and IFN-α2 in the plasma and ETA supernatants of matched patients. Paired individual
 405 values are shown. **, p<0.01; ***, p<0.001.

406




Figure 2

407
 408 **Figure 2: Relative proportion of innate T cells in PBMC and ETA of Covid-19 patients.**
 409 **A**, Flow cytometry analyses of innate T cells in the blood of healthy donors (n = 20) and severe
 410 Covid-19 patients (n = 30). Representative dot plots of MAIT, iNKT and γδT cells from healthy
 411 donors and Covid-19 patients as percentage of CD3⁺ live cells are shown in the left panel.
 412 Proportion of γδT subsets is shown as percentage of total γδT cells. Individuals and means ±
 413 SEM are shown in the right panel. Of note, iNKT cells could not be detected in 4 patients. **B**,
 414 Comparative analysis of MAIT and γδT cell subsets in blood and ETA of 12 Covid-19 patients
 415 with analyzable lymphocyte compartment in ETA. Representative dot plots are shown in the
 416 left panel. Individuals and means ± SEM are shown in the right panel. **C**, Levels of CXCL10
 417 and CXCL12 in ETA supernatants according to the presence (n = 12) or not (n = 8) of iT cells.
 418 Individuals and means ± SEM are shown. ns, not significant; *, p<0.05; ***, p<0.001.

419
 420
 421





Figure 3

422
 423 **Figure 3: Functional analysis of innate T cells during severe Covid-19.** **A**, Flow cytometry
 424 analyses of CD69 and PD-1 expression on MAIT, $\gamma\delta$ T and iNKT cells in the blood of healthy
 425 donors (n = 20) and severe Covid-19 patients (n = 30). Individuals and means \pm SEM are shown.
 426 **B**, Relative proportions of CD69⁺ and PD-1⁺ iT cells in the blood and ETA of matched patients.
 427 Paired individual values are shown. **C**, Intracellular staining for IFN- γ and IL-17A of
 428 PMA/ionomycin-activated PBMC. Representative dot plots for iT cells are depicted in the left
 429 panel. Individuals and means \pm SEM are shown on the right panel. **D**, Levels of IFN- γ and IL-
 430 17A in the plasma and ETA supernatants of matched patients. Paired individual values are
 431 shown. **E**, Levels of IFN- γ and IL-17A in the ETA supernatants according to the presence (n =
 432 12) or not (n = 8) of iT cells. ns, not significant; *, p<0.05; **, p<0.01; ***, p<0.001.

433



434

435 **Figure 4: Kinetic analysis of the frequency and phenotype of innate T cells in severe**
 436 **Covid-19 patients. A-C, Flow cytometry analyses of relative proportion and CD69 and PD-1**
 437 **expression on MAIT (A), $\gamma\delta$ T (B) and iNKT (C) cells in the blood of critically ill Covid-19**
 438 **patients at days 1 (n = 30), 7 (n = 27) and 14 (n = 14). Kinetics plots showing mean value for**
 439 **each patient (each grey line corresponds to one patient). Median values for each parameters**
 440 **were plotted in black. D, Spearman's rank correlation of CD69 expression on blood iT cells and**
 441 **hypoxia levels in Covid-19 patients. ns, not significant; *, p<0.05; **, p<0.01; ***, p<0.001.**

442

443

Age (years), median (IQR)	64 (57; 67)
Male / Female ratio	2/1
Body Mass Index (kg/m ²)	31 (28; 32)
Comorbidities	
Hypertension, n (%)	12 (46.7)
Type 2 diabetes	9 (30)
Active smoking	0
Chronic respiratory failure	0
Chronic renal failure	1 (3.3)
Cardiovascular disease	3 (10)
Immunosuppression	1(3.3)
SAPS2	32 (22; 36)
SOFA	4 (2; 6)
Invasive mechanical ventilation on admission	20 (66.7)
Laboratory data	
Lymphocytes (x10 ⁹ /L), median (IQR)	0.715 (0.510; 0.998)
Neutrophils (x10 ⁹ /L), median (IQR)	6.25 (4.3; 7.52)
CRP (mg/L), median (IQR)	187.7 (83.8; 258)

444


445

Table 1: Clinical and laboratory information of the study patients.


446



447
448 **Supplemental Figure 1: Chest computed tomography scan of Covid-19 patients.**
449 Representative thoracic computed tomography scanning of healthy volunteer and critically ill
450 Covid-19 patient.



451 **Supplemental Figure 2: Evaluation of TCR internalization in MAIT and iNKT cells. A,**
452 Mean intensity fluorescence of TCR expression on MAIT and iNKT cells from control (n = 20)
453 or Covid-19 patients (n = 30) based on TCR Vα7.2 and PBS57-CD1d tetramer staining
454 respectively. Individuals and means ± SEM are shown. **B,** Flow cytometry analysis of TCR
455 Vα7.2 expression using surface vs intracellular staining. Representative dot plots of 4 control
456 and 4 Covid-19 patients are shown. ns, not significant; ***, p<0.001.



457

458 **Supplemental Figure 3: Plasma levels of IL-18 in critically ill Covid-19 patients.** Levels of
459 IL-18 in the plasma of healthy donors (n = 10) and severe Covid-19 patients (n = 30).
460 Individuals and means \pm SEM are shown. ***, $p < 0.001$.

461

462 **Supplemental Table 1: List of anti-human monoclonal antibodies**

463

Epitopes	Clone	Fluorophore(s)	Manufacturers
CD3	OKT3	APC	BioLegend
IL-17A	BL168	APC	BioLegend
CD45	2D1	APC/Cy7	BioLegend
CD4	OKT4	APC/Cy7	BioLegend
TCR Vδ2	B6	FITC	BioLegend
TCR Vα7.2	3C10	FITC	BioLegend
CD3	HIT3a	FITC	BioLegend
IFN-γ	4S.B3	PE	BioLegend
CD69	FN50	PE	BioLegend
PD-1	A17188B	PE-Cy7	BioLegend
CD161	HP-3G10	PerCP	BioLegend
TCR γ/δ	B1	PerCP-Cy5.5	BioLegend
TCR Vδ1	REA173	VioBlue	Miltenyi Biotec

464

465